NT-proBNP is a well-established biomarker for risk stratification in patients with AS, with prognostic value in both symptomatic and asymptomatic stages.10 It has been increasingly incorporated into longitudinal surveillance strategies aimed at detecting early signs of disease progression and decompensation.11 Notably, in the multicentre, randomized EARLY TAVR trial, NT-proBNP was used as part of a predefined algorithm to trigger early intervention. This evidence concerns the gene NPPB and aortic stenosis.